Insight Molecular Diagnostics (IMDX) Capital Expenditures (2015 - 2026)

Insight Molecular Diagnostics (IMDX) has 12 years of Capital Expenditures data on file, last reported at $613000.0 in Q1 2026.

• Quarterly Capital Expenditures rose 99.67% year-over-year to $613000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.5 million (up 336.92% YoY) and the FY2025 annual result came in at $3.2 million, up 517.25% from the prior year.
• Capital Expenditures declined to $613000.0 in Q1 2026 per IMDX's latest filing, from $1.5 million in the prior quarter.
• The five-year high for Capital Expenditures was $1.6 million in Q1 2022, with the low at -$564000.0 in Q3 2023.
• Average Capital Expenditures over 5 years is $556933.3, with a median of $349000.0 recorded in 2025.
• Year-over-year, Capital Expenditures tumbled 165.66% in 2023 and soared 1179.17% in 2025.
• Insight Molecular Diagnostics' Capital Expenditures stood at $802000.0 in 2022, then slumped by 67.08% to $264000.0 in 2023, then retreated by 18.94% to $214000.0 in 2024, then surged by 591.12% to $1.5 million in 2025, then slumped by 58.55% to $613000.0 in 2026.
• Business Quant data shows IMDX's Capital Expenditures at $613000.0 in Q1 2026, $1.5 million in Q4 2025, and $1.0 million in Q3 2025.